1 High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants

2 <u>underlying pituitary hormone deficiency</u>

3

5	
4	Peter Gergics ^{1a} , Cathy Smith ^{1a} , Hironori Bando ^{1,12a} , Alexander A. L. Jorge ^{2a} , Denise Rockstroh-
5	Lippold ^{3a, 13} , Sebastian Vishnopolska ^{4a} , Frederic Castinetti ^{5a} , Mariam Maksutova ¹ , Luciani
6	Renata Silveira Carvalho ⁶ , Julia Hoppmann ^{3, 14} , Julian Martinez Mayer ⁴ , Frédérique Albarel ⁵ ,
7	Debora Braslavsky ⁷ , Ana Keselman ⁷ , Ignacio Bergadá ⁷ , Marcelo Martí ⁸ , Alexandru Saveanu ⁵ ,
8	Anne Barlier ⁵ , Rami Abou Jamra ¹¹ , Michael H. Guo ^{9, 15} , Andrew Dauber ^{10,16} , Marilena
9	Nakaguma ⁶ , Berenice B Mendonça ⁶ , A Bilge Ozel ¹ , Qing Fang ¹ , Qianyi Ma ¹ , Jun Z. Li ¹ , Thierry
10	Brue ⁵ *, María Ines Pérez Millán ⁴ *, Jacob O. Kitzman ¹ *, Ivo JP Arnhold ⁶ *, Roland Pfaeffle ^{3,11} *,
11	Sally A. Camper ¹ *
12	
13	co-first author (^a)
14	* co-corresponding authors
15	
16	¹ Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA
17	² Genetic Endocrinology Unit (LIM25), Division of Endocrinology, Hospital das Clinicas da
18	Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil
19	³ Department of Women's and Child Health, Division of Pediatric Endocrinology, University
20	Hospital Leipzig, Leipzig, Germany
21	⁴ Instituto de Biociencias, Biotecnología y Biología Traslacional (IB3), Departamento de
22	Fisiología, Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad
23	de Buenos Aires, Ciudad de Buenos Aires, Argentina
24	⁵ Aix Marseille University II, Hôpital Conception, Marseille, France

- ⁶ Developmental Endocrinology Unit, Laboratory of Hormones and Molecular Genetics LIM/42,
- 26 Division of Endocrinology, Hospital das Clinicas da Faculdade de Medicina da Universidade de
- 27 São Paulo (FMUSP), São Paulo, Brazil
- 28 ⁷ Centro de Investigaciones Endocrinológicas "Dr. César Bergadá", (CEDIE), FEI CONICET –
- 29 División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires,
- 30 Argentina
- ⁸ Instituto de Química Biología en Exactas y Naturales (IQUIBICEN-CONICET), Facultad de
- 32 Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad de Buenos Aires,
- 33 Argentina.
- ⁹ Division of Endocrinology, Boston Children's Hospital and Department of Genetics, Harvard
- 35 Medical School, Boston, Massachusetts, USA
- ¹⁰ Cincinnati Center for Growth Disorders, Division of Endocrinology, Cincinnati Children's
- 37 Hospital Medical Center, Cincinnati, Ohio, USA
- ¹¹ Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany
- ¹² Current Address: Division of Diabetes and Endocrinology, Kobe University Graduate School
- 40 of Medicine, Kobe, Japan
- 41 ¹³ Current Address: Beckman Coulter, Krefeld, Germany
- 42 ¹⁴ Current Address: Division of Paediatric Endocrinology and Diabetes, Department of
- 43 Paediatric and Adolescent Medicine, University of Luebeck, Germany
- 44 ¹⁵ Current Address: Department of Neurology, University of Pennsylvania, Philadelphia, PA,
- 45 19104, USA
- ¹⁶ Current Address: Division of Endocrinology, Children's National Hospital, Washington, D.C.
- 47 20010, USA
- 48
- 49 Email, ORCID ID
- 50 Peter Gergics gergicsp@gmail.com, http://orcid.org/0000-0002-3480-896X

- 51 Cathy Smith: smithcat@umich.edu, https://orcid.org/0000-0003-1518-9320
- 52 Hironori Bando: hbando@med.kobe-u.ac.jp, https://orcid.org/0000-0002-7421-2714
- 53 Alexander A L Jorge: alexj@usp.br, https://orcid.org/0000-0003-2567-7360
- 54 Denise Rockstoh-Lippold: d.rockstroh@gmx.de, https://orcid.org/0000-0003-1874-2363.
- 55 Sebastian Vishnopolska: sebasvishno@gmail.com https://orcid.org/0000-0002-1729-9948
- 56 Frederic Castinetti: Frederic.CASTINETTI@ap-hm.fr, https://orcid.org/0000-0002-1808-8800
- 57 Mariam Maksutova: mmaksut@umich.edu
- 58 Luciani Carvalho: lucianic@gmail.com, https://orcid.org/0000-0002-7313-2130
- 59 Julia Hoppmann: Julia.Hoppmann@uksh.de, https://orcid.org/0000-0003-1436-1707
- 50 Julian Martinez Mayer: julianmm.7@gmail.com, https://orcid.org/0000-0003-3696-7291
- 61 Frederique Albarel: Frederique.ALBAREL@ap-hm.fr, https://orcid.org/ 0000-0002-6995-2590
- 62 Debora Braslavsky: dbraslavsky@cedie.org.ar, http://orcid.org/0000-0002-4501-7610
- 63 Ana Keselman: keselman@cedie.org.ar, http://orcid.org/0000-0002-5612-0445
- 64 Ignacio Bergadá: ibergada@cedie.org.ar, https://orcid.org/0000-0001-6546-1949
- 65 Marcelo Martí: marti.marcelo@gmail.com, https://orcid.org/0000-0002-7911-9340
- 66 Alexandru Saveanu: Alexandru.SAVEANU@ap-hm.fr, https://orcid.org/0000-0001-6365-1538
- 67 Anne Barlier: anne.barlier@ap-hm.fr, https://orcid.org/0000-0002-3740-6173
- Rami Abou Jamra: rami.aboujamra@medizin.uni-leipzig.de, https://orcid.org/0000-0002-1542 1399
- 70 Michael H. Guo: mhguo1@gmail.com, https://orcid.org/0000-0002-1357-6389
- 71 Andrew Dauber: adauber@childrensnational.org, https://orcid.org/0000-0003-4890-0262
- 72 Marilena Nakaguma: mari.nakaguma@gmail.com, https://orcid.org/0000-0001-7962-8156
- 73 Berenice Mendonça: beremen@usp.br, https://orcid.org/0000-0003-1762-1084
- 74 A Bilge Ozel: aozel@umich.edu, http://orcid.org/0000-0002-1112-4258
- 75 Qing Fang: qing.fang@regeneron.com, https://orcid.org/0000-0002-8808-8523
- 76 Qianyi Ma: qzm@umich.edu, http://orcid.org/0000-0002-6555-7446
- Jun Z. Li: junzli@med.umich.edu, http://orcid.org/0000-0001-6727-0812.
- 78 Thierry Brue: Thierry.BRUE@ap-hm.fr, https://orcid.org/0000-0001-8482-6691
- 79 Maria Inés Pérez Millán: mipmillan@gmail.com, https://orcid.org/ 0000-0002-0486-109X
- 80 Jacob O. Kitzman: kitzmanj@umich.edu, https://orcid.org/0000-0002-6145-882X
- 81 Ivo J P Arnhold: iarnhold@usp.br, https://orcid.org/0000-0003-1739-1354
- 82 Roland Pfäffle: Roland.Pfaeffle@medizin.uni-leipzig.de, https://orcid.org/0000-0001-6754-3681
- 83 Sally A Camper: scamper@umich.edu, https://orcid.org/0000-0001-8556-3379
- 84 The authors have no conflicts of interest to disclose
- 85
- 86 Key words: alternative splicing, growth hormone deficiency, multiplexed assays of variant
- 87 effects, transcriptional regulation

88 Abstract

89 Pituitary hormone deficiency occurs in ~1:4,000 live births. Approximately 3% of the cases are 90 due to mutations in the alpha isoform of POU1F1, a pituitary-specific transcriptional activator. 91 We found four separate heterozygous missense variants in unrelated hypopituitarism patients 92 that were predicted to affect a minor isoform, POU1F1 beta, which can act as a transcriptional 93 repressor. These variants retain repressor activity, but they shift splicing to favor the expression 94 of the beta isoform, resulting in dominant negative loss of function. Using a high throughput 95 splicing reporter assay, we tested 1,080 single nucleotide variants in POU1F1. We identified 96 113 splice disruptive variants, including 23 synonymous variants. We evaluated separate 97 cohorts of hypopituitarism patients and found two different synonymous splice disruptive 98 variants that co-segregate with hypopituitarism. This study underlines the importance of 99 evaluating the impact of variants on splicing and provides a catalog for interpretation of variants 100 of unknown significance in the POU1F1 gene.

101 Introduction

POU1F1 (formerly PIT-1) is a signature pituitary transcription factor that directly 102 103 regulates the transcription of growth hormone (GH), prolactin (PRL), and both the alpha (CGA) 104 and beta (*TSHB*) subunits of thyroid stimulating hormone^{1,2}. In mice, *Pou1f1* is expressed after the peak expression of *Prop1* at E14.5 and remains expressed into adulthood^{3,4}. A well-105 106 characterized mutant of *Pou1f1* (*Pit1^{dw/dw}*) carries a spontaneous missense mutation (p.W251C) in the homeodomain that disrupts DNA binding^{4,5}. The homozygous mutant mice have no 107 108 somatotrophs, lactotrophs or thyrotrophs except for the Poulf1-independent rostral tip 109 thyrotrophs^{4,6-8}. In humans, loss of *POU1F1* function typically results in GH, TSH and PRL 110 deficiency⁹. 111 *POU1F1* undergoes an evolutionarily conserved program of alternative splicing^{10,11}, 112 resulting in a predominant isoform, alpha, that acts as a transcriptional activator and a minor isoform, beta, that acts as a transcriptional repressor¹²⁻¹⁴. In the human pituitary gland, the beta 113 isoform comprises approximately 1-3% of *POU1F1* transcripts ^{10,15}. The POU1F1 beta isoform 114 115 transcript is created by utilization of an alternative splice acceptor sequence for exon 2, located 116 78 bp upstream of the alpha acceptor, resulting in a 26 amino acid insertion that encodes an 117 ETS1 binding domain. This insertion, which is absent in the alpha isoform, disrupts the 118 transactivation domain at amino acid 48. The POU1F1 alpha and beta isoforms have different 119 activities depending on the context of the target gene¹². For example, the POU1F1 alpha 120 isoform activates its own expression, but the beta isoform does not, and the beta isoform 121 interferes with alpha isoform mediated activation¹⁴. 122 The first case of a recessive POU1F1 loss of function was described in a patient with CPHD born to consanguineous parents¹⁶, and since then thirty-seven unique variants in 123 POU1F1 have been reported in patients with CPHD or IGHD¹⁷⁻²³. A few dominant negative 124 125 mutations have been reported: p.P76L alters the transactivation domain and causes completely penetrant IGHD²⁴, p.K216E interferes with the ability of POU1F1 to interact with retinoic acid 126

127	receptors and p300 ²⁵ , and p.R271W interferes with the ability of POU1F1 to be tethered to the
128	nuclear matrix through MATR3, SATB1 and CTNNB1 ²⁶ . All of the reported mutations are
129	located in domains shared by the alpha and beta isoforms of POU1F1 and were functionally
130	tested using the alpha isoform only.
131	We found four missense variants, in four independent families, that shift splicing to favor
132	the POU1F1 beta isoform almost exclusively, while retaining its transcriptional repressor activity
133	on the POU1F1 enhancer. We used a high throughput assay to identify 113 variants in and
134	around exon 2 that cause exon skipping, cryptic splicing and isoform switching. We used this
135	catalog to evaluate additional families with hypopituitarism and identified two unrelated patients
136	carrying synonymous POU1F1 variants that affect its splicing without changing the amino acid
137	sequence. This study underscores the importance of evaluating splicing defects as a disease
138	mechanism.

139 Methods

140 Patients

141 The studies were approved by ethical committees: the local Comite de Eticae Pesquisa da 142 Faculdade de Medicina da Universidade de São Paulo (CEP-FMUSP) and the national Comite 143 nacional de etica em pesquisa (CONEP) CAAE, 06425812.4.0000.0068; the Ethics Committee 144 of the Faculty of Medicine, University of Leipzig (UL), Karl-Sudhoff-Institute for Medical History 145 and Natural Sciences, Käthe-Kollwitz-Straße 82, 04109 Leipzig, Germany; and the Comité de 146 Ética en Investigación (Research Ethics Committee) of the Hospital de Niños Ricardo Gutierrez 147 (HNG), Gallo 1330, Ciudad autónoma de Buenos Aires, Argentina (CEI № 16.06). The 148 GENHYPOPIT network collected anonymized information in a database declared to health 149 authorities in accordance with local regulations at Aix-Marseille Université (AMU) - Conception 150 Hospital (Assistance Publique - Hôpitaux de Marseille, AP-HM), and a declaration was made to 151 the National Commission for Data Protection and Liberties (CNIL-France): 1991429 v 0. 152 Patients or their parents signed a written informed consent to participate. Families 1, 3, and 6 153 are historical cases that were referred to the GENHYPOPIT network for genetic testing. Limited 154 information is available for Families 1 and 3, and they were lost for follow up. The University of 155 Michigan Institutional Review Board (UM) found the study exempt because patient DNA 156 samples were anonymized before exome sequencing at UM. 157 DNA sequencing of patient samples

158 Individuals from Families 1, 2, 4, and 5 underwent whole exome sequencing (WES).

159 Representative POU1F1 variants in Family 3 and 6 were discovered in a traditional CPHD

- 160 candidate gene screening using Sanger sequencing (*PROP1*, *POU1F1*, *LHX3* and *LHX4*).
- 161 WES of Families 1 and 5 was carried out at University of Michigan as previously described¹⁷.

162 WES of Family 2 was performed at the Broad Institute as previously described²⁷. WES of

163 Family 4 was performed at the Institute of Human Genetics at University of Leipzig.

164 Expression vectors and cell culture

165 The open reading frame of either POU1F1 isoform alpha (NM 000306.3) or beta 166 (NM_001122757.2) was cloned into pcDNA3.1+/C-(K)-DYK. Site directed mutagenesis was 167 used to obtain each of the variant POU1F1 beta isoforms: p.S50A, p.I51S, p.L52W, and 168 p.S53A (Genscript). A firefly luciferase reporter gene was constructed in pNBm81-luc with 14 169 kb of the mouse Poulf1 5' flanking sequences that includes early and late enhancers and the 170 promoter, and 13 bp of the 5'UTR. Cloning was performed with Infusion HD (Clontech) or 171 NEBuilder HiFi DNA Assembly (New England Biolabs). Plasmid sequences were confirmed by 172 Sanger sequencing. The pRL-TK renilla (Promega) was used as a normalization control and 173 pcDNA3.1(-) (Thermo-Fisher) to keep the total DNA constant. COS-7 cells were purchased 174 from the American Type Culture Collection. Cells were maintained in Dulbecco's modified eagle 175 medium (DMEM, Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum and pen-176 strep (Gibco). Plasmids were transiently transfected into COS-7 cells using ViaFect 177 Transfection Reagent (Promega, Madison, WI, USA). Luciferase activities were measured as 178 suggested by the manufacturer (Dual-luciferase assay system; Promega). 179 Exon trapping assay 180 Human POU1F1 exon 2, flanked by partial intron 1 (85 bp upstream) and intron 2 (178 bp 181 downstream), was cloned into the BamHI cloning site of the pSPL3 plasmid (Invitrogen) to 182 create an exon trapping plasmid with a total insert size of 413 bp. Similarly, a minigene exon 183 trapping plasmid was constructed that included the last 85 bp of intron 1 and the first 85 bp of 184 intron 5, for a total insert size of 3,442 bp including exons 2, 3, 4, and 5. Site directed 185 mutagenesis was used to create the desired variants. Plasmids were transiently transfected 186 into COS-7 cells. Total RNA was purified with RNeasy mini (Qiagen). After reverse 187 transcription, we analyzed exon trapping using RT-PCR with following primers; Primers SD6 188 Forward (5'-TCT GAG TCA CCT GGA CAA CC- 3') and SA2 reverse (5'- ATC TCA GTG GTA 189 TTT GTG AGC -3')²⁸.

190 POU1F1 Saturation Mutagenesis

The cloned *POU1F1* fragment in pSPL3 was divided into four overlapping tiles of 150 bp each, spanning exon 2 plus flanking introns (79 bp upstream to 131 bp downstream). Mutant tile libraries containing every possible single nucleotide variant were synthesized as a single 150mer oligonucleotide pool by Twist Bio. HiFi Assembly was used to replace each wild type tile with the respective mutant tile library amplified from the oligo pool. The resulting mutant minigene library pools were transformed in 10b *E. coli* (New England Biolabs), with a minimum coverage of 90 clones per mutation.

198 Mutant library barcoding and sequencing

199 To tag each mutant minigene clone with a unique barcode, a random barcode sequence (N_{20}) 200 was inserted by HiFi Assembly into the MscI site within the common 3' UTR. Subassembly 201 sequencing²⁹ was used to pair each 3' UTR barcode with its linked variant(s) in cis. Briefly, a 202 fragment starting with the POU1F1 insert and ending at the N_{20} barcode (2.2 kb downstream) 203 were amplified from the plasmid library DNA by PCR using 5'-phosphorylated primers. The 204 resulting linear fragment was re-circularized by intramolecular ligation using T4 DNA ligase 205 (NEB), to bring each barcode in close proximity to the mutagenized region. From this re-206 circularized product, paired-end amplicon sequencing libraries were generated, such that each 207 reverse read contained a plasmid barcode and the paired forward read contained a sequence from the associated POU1F1 insert. Barcode reads were clustered with starcode³⁰ (arguments 208 209 "-d 1 -r 3") to generate a catalog of known barcodes. Variants were called within each barcode group using freebayes³¹ and filtered to require majority support, and read depth \geq 4 along the 210 211 entire region targeted for mutagenesis.

212 Pooled exon-trap transfection and RNA-seq

COS-7 cells were plated at 5x10⁶ cells/60 mm plate. Each was transfected with 4 ug of the barcoded mutant exon-trap library using ViaFect reagent (3:1 ratio to DNA). After 24 hrs, RNA was purified as above, and 5 ug of total RNA was used to prepare first-strand cDNA using the SuperScript III First-Strand Synthesis kit (Invitrogen) with oligo dT primers. Spliced transcript

was amplified using nested PCR, initially for 6 cycles using the SD6F/SA2R primers, followed by

218 20 cycles using primers SD2F/jklab0046 (TGTAGTCAGTGCCATCTTGGATCT). Paired-end

219 Illumina sequencing libraries were generated by tailing PCR (6 cycles) with a forward primer

220 within the constant upstream exon (GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT

221 AGGGCATAGTGCCATCTTGGATCT) and a reverse primer immediately downstream of the N₂₀

222 barcode (TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGTGAACTGCACTGTG ACA

AGCTGC). Unique dual i5/i7 indices were added by a second round of tailing PCR (6 cycles),

and the resulting products were purified by SPRI bead cleanup and submitted for Illumina

sequencing on a Hiseq 4000 and/or Novaseq instrument.

226 RNA-seq processing pipeline

227 Reverse reads containing the plasmid barcode were searched for exact match to a known

barcode from the plasmid library. Forward reads containing the spliced sequence were mapped

to a variant-specific reference consisting of the POU1F1 exon trap reference sequence with the

respective mutation introduced in silico, using GMAP³² (arguments "-t 8 -f samse --microexon-

231 spliceprob=1.0 --allow-close-indels=2"). From the spliced reads, an isoform catalog was tallied

requiring each isoform to be represented by at least three distinct barcodes and nine reads.

233 Spliced reads associated with each barcode were tallied to produce per-barcode isoform usage

counts, and percent spliced in (PSI) fractions. Barcodes corresponding to the same POU1F1

variant were then aggregated (weighted by the number of reads obtained) to generate for each

variant a mean PSI score for all known isoforms. Isoforms not matching a known isoform (beta,

skip, or alpha) were placed in a catch-all category called "OTHER". Barcodes represented by

fewer than three reads were discarded from further analyses. Then, within each biological

replicate, the mean PSI score was standardized, and variants with a *z*-score \geq 1.5 for the beta,

skip, or other isoform in at least half of the replicates were nominated as splice disruptive

241 variants.

242 <u>Comparison of bioinformatic predictors</u>

HAL delta_psi scores³³, SPANR zdelta_psi scores³⁴, SpliceAl ds_max scores³⁵, and MMSplice

- 244 delta_logit_psi scores³⁶ were obtained from their original publications without modification. To
- 245 compute per-variant Δ ESRseq scores³⁷, we took the difference between the mean ESRseq z-
- scores of hexamers overlapping a variant position from that of hexamers overlapping the
- 247 corresponding wildtype position. Precision-recall curves were obtained to summarize each
- 248 algorithm's ability to predict the experimental determination of splice disruptiveness. For
- algorithms which output signed scores, area under the curve (prAUC) was separately computed
- using signed and absolute scores as input and the higher prAUC was taken.
- 251 Selection of candidate RNA binding proteins (RBP)
- 252 RNACompete z-scores ³⁸ were obtained from the cisBP-RNA database (http://cisbp-
- 253 rna.ccbr.utoronto.ca). At each position, wild-type and variant-containing z scores were taken as
- the maximum among the overlapping kmers, and the difference taken between the wild-type
- and variant scores. Motifs with high scoring matches (wildtype z>=3) to the wild-type sequence
- in the beta variant cluster (c.143-1 to c.167) were then pursued further.
- 257 Data availability
- 258 Raw sequence reads and processed counts are available at GEO (accession tbd). Jupyter
- 259 notebooks to reproduce the processed dataset from raw counts are posted at GitHub (URL tbd).

260 **Results**

261 Mutations in the POU1F1 beta coding region cause hypopituitarism

262 We initially focused on four cases of hypopituitarism from different cohorts in Europe and South 263 America (Fig. 1A). Affected individuals' presentation was variable, ranging from multiple 264 hormone deficiency with pituitary stalk interruption (Family 1) to isolated GH deficiency (Family 265 2) (Table 1, Suppl. Fig. 1). The affected individuals had severe short stature and responded 266 well to GH therapy (Fig. 1B). To identify causal variants, we performed whole exome 267 sequencing (WES) for individuals in three families. Combined with conventional Sanger 268 sequencing in another family, this revealed four missense variants in exon 2 of the POU1F1 269 beta isoform, each in an unrelated family (Figure 1A, 2A). The four patient POU1F1 missense 270 variants are absent from gnomAD and in-house population-matched exome databases^{39,40}, and 271 they are predicted to be damaging by several bioinformatic algorithms (**Table 1**). Remarkably, 272 these variants clustered in four consecutive codons: c.148T>G (p.S50A), c.152T>G (p.I51S), 273 c.155T>G (p.L52W), and c.157T>G (p.S53A) in NM 001122757.3 (Table 1). Only one of these 274 (c.155T>G, Family 3) appears to be *de novo*; the others were dominantly inherited and co-275 segregate with hypopituitarism phenotypes, except for c.148T>G which was inherited from the apparently unaffected parent in Family 1, indicating that if causal, this variant is incompletely 276 277 penetrant. The other parent in Family 1, the two affected children, and one unaffected relative 278 also carried a variant of uncertain significance, SIX3 p.P74R. No other variants in known 279 hypopituitarism genes were detected. 280 Sequence variants retain POU1F1 beta isoform repressor function 281 We first asked whether these variants disrupt the ability of POU1F1 to bind and transactivate its

we first asked whether these variants disrupt the ability of POUTF1 to bind and transactivate its own promoter⁴¹ using a transient transfection assay (**Figure 2B**). As expected, a *Pou1f1* promoter reporter was strongly activated when co-transfected with cDNA of POU1F1 alpha isoform, which does not include the variant sites. Neither WT POU1F1 beta isoform, nor any of the four patient missense variants, showed significant activation of the *Pou1f1*-luc reporter. Consistent with a repressive role for POU1F1 beta, co-transfection with alpha at a 1:1 ratio
significantly suppressed activation compared to the equivalent amount of alpha isoform alone.
The four POU1F1 beta variants and WT beta repressed POU1F1 alpha activity to a similar

degree.

290 Patient missense variants disrupt normal *POU1F1* splicing to favor the beta isoform

291 Alpha is normally the predominant POU1F1 isoform, but its splice acceptor is predicted to be much weaker than the beta isoform acceptor 78 bp upstream (MaxEntScan⁴²; scores, alpha: -292 293 3.63, beta: 6.96) (Fig. 2C). The beta isoform splice acceptor sequence and coding region are 294 evolutionarily conserved in mammals and birds (Fig. 2D). We reasoned that splice repressor 295 and/or enhancer sequences in POU1F1 may dictate the normal balance of alpha over beta 296 isoforms, and these may be disrupted by the four patient T>G transversions. To test the effect 297 of these variants directly, we cloned POU1F1 exon 2 and portions of the flanking introns into the 298 exon trap splice reporter pSPL3 and introduced each variant by site directed mutagenesis (Fig. 299 2E). These small minigenes were transfected into COS-7 cells, and RNA was analyzed by RT-300 PCR. The wild type minigene produced almost exclusively alpha isoform, while each of the 301 patient variants predominantly produced the beta isoform (Fig. 2F). We also tested splicing with 302 larger minigenes, which contain portions of intron 1 and intron 5 with intact exons 2, 3, 4 and 5 303 as well as introns 2, 3 and 4, and obtained similar results, indicating the additional sequence 304 context does not strongly influence the observed splicing pattern (Fig. 2G). We also tested two 305 previously reported POU1F1 variants in the longer minigene context. The c.214+1 G>T caused 306 skipping of exon 2, as expected, resulting in an in-frame POU1F1 protein that lacks 80% of the transactivation domain⁴³. This variant is associated with mild hypopituitarism. The p.P76L 307 308 variant is located in the transactivation domain, enhances POU1F1 interaction with other proteins, and is associated with severe, dominant IGHD²⁴. The effect of this variant on splicing 309 310 had not been assessed previously, and we found that it produced predominantly alpha isoform 311 expression, indistinguishable from wild type.

312 Saturation mutagenesis screen for splice disruptive effects

We set out to systematically identify splice disruptive variants in POU1F1 exon 2 using a 313 314 massively parallel splice reporter assay. We designed oligonucleotide pools containing every 315 possible single nucleotide variant across exon 2 (150 bp) and 210 bp of the flanking introns 316 (N=1080), and generated libraries in which these allelic series replaced the wild type POU1F1 317 fragment in the pSPL3 reporter. To track the splicing outcomes associated with each mutation, 318 we placed a degenerate 20mer barcode in the downstream 3' UTR. The mutant plasmid library was subjected to subassembly sequencing²⁹ to establish the pairing between each unique 319 320 barcode and its associated POU1F1 mutation. In total, the mutant library contained 255,023 321 distinct barcoded clones, among which 188,772 (74.0%) had exactly one programmed mutation. 322 Nearly every targeted mutation appeared in this library (1070/1080, 99.1%), with a high degree 323 of redundancy (median 75.0 distinct barcodes/mutation, Suppl. Fig. 2).

324 The splice reporter library was transfected as a pool into COS-7 cells and processed 325 similarly to the single mutation constructs. Spliced reporter transcripts were read out en masse 326 using paired-end RNA-seq (Fig. 3A), with each forward read measuring an individual splicing 327 outcome and the paired reverse read containing the 3' UTR barcode which identifies the 328 mutation(s) present in the primary transcript. We performed 14 biological replicates, across 329 which 94.2% (81.8-93.4%, mean 87.4%) of clone library single nucleotide variant associated 330 barcodes were detected. As expected, alpha was the predominant POU1F1 isoform (69.2% of 331 reads overall), followed by exon 2 skipping (25.6%), and beta (1.6%). We created a catch-all 332 category ('Other') for the remaining reads (3.6%) derived from the 262 other isoforms detected. 333 Most of those noncanonical isoforms were only scarcely used; among them, the top 20 334 accounted for >80% of the reads from that category. For each POU1F1 variant, a percent 335 spliced in (PSI) value was computed for each isoform (alpha, skip, beta, other), averaged over 336 the associated barcodes. PSI values were highly reproducible across replicates (median 337 pairwise Pearson's r: 0.92; Suppl. Fig. 3).

338 Splice disruptive variants (SDVs) across *POU1F1* exon 2

339 We assessed the splicing effect of 1,070 single nucleotide variants (Figure 3A and 340 **Supp. Fig. 4**). Of these, 113 (10.6%) were splice disruptive variants (SDVs), which we defined 341 as those which increased usage of beta, skip, or other isoforms by ≥ 1.5 standard deviations. 342 SDVs leading to increased skipping were the most frequent (n = 69/113; 61.1%), followed by 343 those creating other isoforms (n = 34/113; 30.1%), and those which increased beta usage (n =344 29/113; 25.7%), with some variants (n = 19/113; 16.8%) impacting usage of multiple isoforms 345 (Suppl. Fig. 5). Variants leading to each outcome tended to cluster in distinct regions; notably, 346 the beta-increasing SDVs were located near the 5' end of the beta isoform. Intronic SDVs 347 tended to lead to skipping. A few variants that increased skipping were scattered across exon 2, 348 and there was some enrichment in the 5' end of the beta isoform coding region, but most were 349 enriched near splice donor and acceptor sites: 27 of 28 intronic SDVs were within +/- 20 bp of 350 exon 2.

351 SDVs which created novel ("other") isoforms were nearly all located within the coding 352 region unique to the beta isoform and at the alpha isoform acceptor site (n = 33/34; 97.1%). Of 353 these, most (27/34) create a novel acceptor AG dinucleotide that outcompetes the more distal, 354 native alpha acceptor (**Suppl. Fig. 6**). Most of these (19/27) result in a frame-shifted transcript, 355 and all are predicted to undergo non-sense mediated decay due to premature termination 356 codons >50 bp upstream of the final exon junction. In contrast, each of the six mutations in the 357 alpha isoform acceptor dinucleotide activates another cryptic acceptor six bp downstream. 358 leading to in-frame deletion of two codons (Suppl. Fig. 7). Out of 99 mutations creating a GT 359 dinucleotide, only one was used as a novel splice donor, c.290:C>T located 4 bp upstream of 360 the native donor.

We compared these SDVs to the variants found in Families 1-4. All four patient
 missense variants showed strongly increased beta isoform usage (beta isoform z-scores range:
 5.12-6.18), mirroring the results of individual minigene assays (Fig. 3B). Our results also

recapitulate previously described effects of two variants found in CPHD patients: first, an upstream intronic variant c.143-5:A>G⁴⁴ which led to increased beta usage and skipping (beta isoform *z*=3.48, skip *z* =3.13; **Figure 3C**), and an essential splice donor variant c.292+1 G>T which led to near-complete skipping (skip *z*=5.05; **Suppl. Fig. 7**)⁴³.

368 We also examined the incidence of splice disruptive POU1F1 variants in the general 369 population. The gnomAD database contains 93 of the variants measured here; among those, 370 eight (8.6%) are splice disruptive, all which are individually rare (minor allele frequency \leq 371 1.6x10⁻⁵; Suppl. Fig. 8). Overall, variants found in gnomAD were not significantly depleted for 372 splice disruptive effects relative to randomly selected subsets of the tested single nucleotide 373 variants (p=0.60, Fisher's Exact Test). Thus, POU1F1 SDVs are tolerated to a similar extent as 374 other predicted loss of function variants (stop gain, frameshift, splice site), which are observed 375 throughout POU1F1 at low frequencies in gnomAD.

376 Identification of a silent variant in *POU1F1* in a hypopituitarism patient

377 We next examined the splicing impacts of synonymous variants, which would typically 378 be given low priority during genetic screening due to their expected lack of coding impact. Of 379 the 111 synonymous variants tested, 23 were splice disruptive (20.7%; Suppl. Fig. 5). We 380 identified unrelated patients with IGHD carrying two of these synonymous SDV in the beta 381 isoform coding region near the 5' end of exon 2 (Fig. 3C), both of which were absent in 382 gnomAD and population-matched control databases. The first, c.150T>G (p.Ser50=), was 383 found among an Argentinian cohort (n=171) in a family with two individuals with severe short 384 stature and IGHD (Table 1), for whom WES did not reveal any likely pathogenic variants in 385 known CPHD or IGHD genes. The index case had pituitary hypoplasia, and the patient 386 responded well to recombinant GH treatment. The second, c.153T>A (p.lle51=), was found in a 387 French family in relatives with severe IGHD. The parent's DNA was not available for testing, 388 and the parent could be an unaffected carrier or an example of gonadal mosaicism. Each of

these two silent variants increased beta isoform usage (beta z=5.33 for c.150T>G; beta z=1.79

390 for c.153T>A) to a degree similar to that of the four patient missense variants.

391 Comparison to bioinformatic splicing effect predictions

392 We examined how scores from splicing effect prediction algorithms compared with these 393 experimental measurements. We scored each single nucleotide variant in the targeted region of *POU1F1* using SpliceAl³⁵, MMSplice³⁶, SPANR³⁴, HAL³³ and ESRseg scores³⁷. Among these, 394 395 only SpliceAI predicted a high density of SDVs specific to the exon 2 beta region surrounding 396 the patient variants (Suppl. Fig. 9). To benchmark each bioinformatic predictions, we took our 397 SDV calls as a truth set and computed for each algorithm the area under the precision recall 398 curve (**Suppl. Fig. 10**). SpliceAl was the most highly concordant with our results for both exonic 399 variants (prAUC=0.790 vs other tools' range: 0.329-0.430) and intronic variants (prAUC=0.661 400 versus other tools' range: 0.526-0.604). Nevertheless, SpliceAl disagreed with our 401 measurements for numerous variants: at the minimum threshold needed to capture all six 402 patient variants as disruptive (SpliceAl deltaMax score≥0.19), it achieved 67.3% sensitivity 403 (n=37 SDVs not predicted by SpliceAI) and 97.2% specificity (n=27 variants predicted by 404 SpliceAI but not identified by our assay) for predicting the SDVs we identified. The degree of 405 concordance with SpliceAI was largely insensitive to the specific measurement threshold used 406 to call variants as splice disruptive in our screen (Suppl. Fig. 10). Additional studies will be 407 required to resolve the discordant predictions for variants observed during clinical screening. 408

409 **Discussion**

We found six unrelated cases with CPHD or IGHD that can be explained by variants that 410 411 shift splicing to favor the repressive beta isoform POU1F1. The missense variants, p.S50A, 412 p.I51S, p.L52W, and p.S53A, retain repressive function. They act in a dominant negative 413 manner by suppressing the ability of the POU1F1 alpha isoform, expressed from the wild-type 414 allele, to transactivate expression of POU1F1 and other downstream target genes. Using 415 saturation mutagenesis coupled to a high-throughput RNA-seg splicing readout, we 416 systematically tested nearly every possible single nucleotide variant in or near POU1F1 exon 2 417 for splice disruptive potential (**Supplemental Table 1**). We identified 113 SDVs which similarly 418 activate usage of the beta isoform or cause other aberrant splicing outcomes such as exon 419 skipping. 420 This screen accurately identified the four missense variants we identified in patients. It 421 also identified 23 synonymous splice disruptive variants, or over one-fifth of the possible 422 synonymous variants in POU1F1 exon 2. We identified two of these synonymous SDVs in 423 unrelated families with IGHD, c.150T>G (p.Ser50=) and c.153T>A (p.Ile51=), each of which 424 increased beta isoform usage similarly to the four patient missense variants that initially drew 425 our attention. These findings underscore the need to closely examine variants for splice 426 disruptive effects, particularly synonymous variants that could be overlooked by traditional 427 exome sequencing filtering pipelines. 428 The clinical features varied amongst the six families, although they were consistent

within a family. Families 1, 3, and 4 presented with CPHD, while Families 2, 5, and 6 had IGHD.
Moreover, Family 4 developed hypocortisolism. The reason for this variability in presentation is
unknown. However, there are precedents for variable clinical features and incomplete
penetrance with other cases of hypopituitarism¹⁸. Approximately 50% of IGHD progresses to
CPHD, and this can even occur when the mutated gene is only expressed in GH-producing cells,
i.e. *GH1*⁴⁵. Even individuals with the same *POU1F1* mutation (i.e. p.E230K) can present with

either IGHD or CPHD⁴⁶, indicating a contributing role for genetic background, epigenetic, and/or 435 436 environmental factors. Both affected relatives in Family 1 had stalk disruption, a phenotype not 437 currently associated with any other *POU1F1* variants. This feature may be due to the presence 438 of an additional variant in SIX3, p.P74R, that was carried by two unaffected relatives. 439 Heterozygous loss of function of SIX3 is associated with incompletely penetrant and highly 440 variable craniofacial abnormalities, including CPHD and holoprosencephaly, and there is 441 precedent in mice for Six3 loss of function to exacerbate the phenotype caused by mutations in other CPHD genes such as Hesx1⁴⁷⁻⁴⁹. 442

443 Autosomal dominant inheritance is clear in Family 2, in which there were four affected 444 individuals over three generations, as well as Families 4, 5, and 6. POU1F1 acts as a 445 heterodimer⁵⁰. Some other dominant mutations in *POU1F1* act as negative effectors due to the 446 ability of the mutant protein to interfere with the action of the wild type protein produced from the other allele^{25,51,52}. The negative effect of POU1F1 beta on the transactivation properties of 447 POU1F1 alpha are context dependent, with differential effects on Gh, Prl and Pou1f1 reporter 448 genes⁵³. The strongest effect was reported for autoregulation of POU1F1 expression via the 449 450 distal, late enhancer; dampening the auto-activation of POU1F1 expression, and adversely 451 affecting differentiation of the entire POU1F1 lineage and result in anterior lobe hypoplasia. 452 The lack of significant depletion for POU1F1 SDVs among ostensibly healthy adult 453 populations underscores the possibility of variable expressivity and/or penetrance for POU1F1 454 splice-disruptive variants. This is consistent with the apparently unaffected parents in Families 455 1 and 6. A subset of these variants, like c.222T>C which disrupts the alpha isoform acceptor 456 and causes a frame-preserving two-codon deletion, may retain partial or complete function. Still

457 others, may cause loss-of-function without dominant negative effects, and would not be

458 expected to be strongly depleted.

In human genes, canonical splice site motifs contain less than half of the information
 content needed for proper splicing ⁵⁴. Additional specificity is provided by short (6-10 nt) motifs

461 termed exonic or intronic silencers and enhancers, which are bound by RNA binding proteins that promote or antagonize splicing⁵⁵. Although transcriptome-wide atlases have been 462 developed to map these sites^{37,56}, and derive motif models⁵⁷, it often remains unclear how 463 464 genetic variants impact their binding and in turn the eventual splicing output. Our splicing effect 465 map identifies a cluster of SDVs at the 5' end of the POU1F1 exon 2, each of which increases 466 the usage of the normally repressed beta isoform. These results suggest the presence of an 467 exonic splice silencer (ESS) which may normally suppress utilization of the beta isoform acceptor. We mined the cisBP-RNA database ³⁸ and identified nine candidate motifs with 468 469 strong matches to the U-rich wild-type sequence in this region (c.143-1 to c.167) corresponding 470 to known splicing factors including ELAVL1 (HuR), RALY, TIA1, and U2AF2 (Suppl. Fig. 11). 471 All six patient variants replaced a U with another base (G in 5 of 6 bases), which may disrupt 472 these motifs at high information content positions (Suppl. Fig. 12). Other variants predicted to 473 disrupt these motifs tended to be beta-promoting more often than neutral in our map (p < 0.01, 474 Fisher's Exact test). These trends suggest that U-rich ESS serves to inhibit production of 475 POU1F1 beta and this inhibition is disrupted by CPHD-associated variants, although 476 conclusively identifying the specific cognate binding factor will require further study. 477 These results extend the breadth of endocrine disorders caused by disrupted splicing. 478 For example, in a large cohort with IGHD from Itabaianinha, Brazil, affected individuals are 479 homozygous for a mutation in the splice donor dinucleotide (c.57 + 1G > A) in the growth hormone releasing hormone receptor gene (*GHRHR*)⁵⁸. In addition, most mutations that cause 480 481 dominant IGHD type II affect splicing of the growth hormone (GH1) gene⁵⁹. Mutations in splice

negative 17.5 kD isoform of growth hormone that lacks amino acids 32-71⁶⁰. The severity of the
disease is variable and correlates inversely with the ratio of 17.5 to 20 kD GH. Finally, severe
short stature associated with Laron syndrome, or GH resistance, can be caused by generation
of a cryptic splice site in the GH receptor gene. Individuals from El Oro and Loja in southern

sites or splice enhancer sequences result in skipping exon 3 and production of a dominant-

482

Ecuador are homozygous for a p.180E codon variant (GAA to GAG) that do not change the amino acid encoded but create a splice acceptor site 24 nt upstream of the normally utilized site⁶¹. It is notable that antisense oligonucleotide therapies hold promise for treating diseases caused by abnormal splicing, including IGHD^{62,63}.

491 Splicing disruption accounts for a significant minority of the genetic burden in endocrine disorders, as in human genetic disease more generally ^{64,65}. Some estimates from large-scale 492 493 screens indicate that 10% of SNV within exons alter splicing, and a third of all disease associated SNVs impact splicing efficiency⁶⁶. Variants at or near canonical spice sites are 494 readily recognized as pathogenic⁶⁷, and these can be identified predicted with high accuracy by 495 496 algorithms such as SpliceAI. However, for exonic variants, particularly those farther from exon 497 junctions, splicing defects may be more challenging to identify bioinformatically⁶⁸⁻⁷⁰. Efforts to 498 interpret these variants will need to account for the functional impacts of changing the encoded 499 protein sequence as well as its splicing. Finally, as our results illustrate, different variants in a 500 single gene may lead to distinct splicing outcomes with diverse consequences ranging from the 501 straightforward loss-of-function to dominant negative effects.

502

<u>Table 1</u>

Table 1. Clinical and molecular features of affected individuals								
Feature	Family 1		Family 2				Family 3	
Cases	II.1	11.2	I.1	II.2 (index)	11.4	III.1	II.1	
Gender	Male	Female	Male	Female	Male	Female	Female	
Age at diagnosis 1st hormone deficiency / Hormone	<5 yr / GH, TSH	<5 yr / GH, TSH	40s / GH	<5 yr / GH	< 5 yr / GH	<5 yr / GH	<5 yr / GH, TSH, PRL	
Height at diagnosis of GHD (SDS)	na	na	-3.7	-5	-5.3	na	-4	
rhGH treatment (Yes/No)	na	na	No	Yes	Yes	Yes	na	
Final height (cm / SDS)	na	na	150 / -3.7	156.5/-0.9	165/-1.5	na	na	
Pituitary hormone deficiencies	GH, TSH	GH, TSH	GH	GH	GH	GH	GH, TSH, PRL	
Biochemical assesment								
GHSTs	na	na	clonidine, ITT	clonidine, ITT	clonidine	na	na	
Maximum GH peak (ng/ml)	na	na	7.6	0.9	0.5	na	na	
TSH (U/L)	na	na	0.6	0.7	1.7	na	na	
Total T4 (ug/dL)	na	na	6.4	6	5.6-7.3	na	na	
Free T4 (ng/dL)	na	na	0.7	0.6-1.1	0.6-0.9	na	na	
Prolactin (ng/mL)	na	na	na	3.8 (pTRH 12)	3.2-6.6	na	na	
Cortisol (ug/dL)	na	na	na	peak ITT 42	normal	na	na	
LH/FSH	na	na	na	early puberty	normal puberty	na	na	
Pituitary MRI	Disrupted stalk	Disrupted stalk	Normal	Normal	Normal	na	Normal	
Extrapituitary brain MRI	na	na	na	na	na	na	na	
Dysmorphic features	none noted	none noted	none noted	large forehead	none noted	na	na	
Molecular findings (all in heterozygous state)	c.148T T>G	c.148T T>G	c.152T>G	c.152T>G	c.152T>G	c.152T>G	c.155T>G	
	p.S50A	p.S50A	p.I51S	p.I51S	p.I51S	p.I51S	p.L52W	
In silico predictions								
CADD	22.00		23.4				25.8	
SIFT	damaging		damaging				damaging	
PP2		ign	benign				probably damaging	
Mutation taster	disease causing		disease causing				disease causing	

Feature	Eamily 4	Far	nily 5	Family 6		
Cases	1.2 .1		L1	II.1 (index)	II.1 (index)	11.2
Gender	Female	Female	Male	Male	Male	Male
Age at diagnosis 1st hormone deficiency / Hormone	<5 vr / TSH	<5 vr / TSH_GH	preteen / GH	<5 vr / GH	preteen / GH	preteen / GH
Height at diagnosis of GHD (SDS)	-5.42	-3.45	-4.2	-4.15	na	na
rhGH treatment (Yes/No)	Yes	Yes	Yes	Yes	Yes	na
Final height (cm / SDS)	150.9 /-2.67	still growing	147.9 / -3.66	still growing	na	na
Pituitary hormone deficiencies	GH, TSH, PRL, (ACTH†)	GH, TSH, PRL, (ACTH†)	H, TSH, PRL, (ACTH†) GH GH		GH	GH
Biochemical assesment						
GHSTs	glucagon, insulin, clonidine	Basal neonatal	Insulin- Ldopa	Arginine-Clonidine	ITT	ITT
Maximum GH peak (ng/ml)	ND	ND	2.9*	2.7**	3.7 mUI/I	3.6 mU/l
TSH (U/L)	na	0.28	na	3.4	normal	normal
Total T4 (ug/dL)	na	na	na	na	na	na
Free T4 (ng/dL)	na	0.4	0.9	1.2	na	na
Prolactin (ng/mL)	2.0 mU/l	9 mU/l	8.3 4.4		na	na
Cortisol (ug/dL)	treated in 20's	36.2 nmol/l	13	13.2	na	na
LH/FSH	Delayed puberty, spontaneous pregnancy	Normal	Spontaneous puberty	0.1/0.75	spontaneous puberty	na
Pituitary MRI	Normal	Normal	na	APH	Normal	na
Extrapituitary brain MRI	1 cm left frontal and parietal lobe abnormality	Normal	Normal	Normal	na	na
Dysmorphic features	Intellectual disability, delayed puberty, strabismus, astigmatism, nystagmus, dysplastic thyroid gland	Macroglossia, bilateral hearing impairment, developmental delay, dysplastic thyroid gland	none noted	Short stature, frontal bossing, high pitched voice	na	na
Molecular findings (all in heterozygous state)	c.157T>G	c.157T>G	c.150T>G	c.150T>G	c.153T>A	c.153T>A
	p.S53A	p.S53A	p.S50=	p.\$50=	p.151=	p.151=
In silico predictions						
CADD	18.65					
SIFT	damaging					
PP2	benign					
Mutation taster	disease caus	ing				

na: not available							T	
GHSTs: growth hormone stimulation tests, ND: non-detectable, MRI: magnetic resonance imaging, rhGH: recombinant human growth hormone, APH: anterior pituitary hypoplasia								
ITT: insulin-tolerance test								
*Cut-off 4.8 ng/ml; **cut-off 10 ng/ml								
†diagnosed in late 20s for I.2 and newborn for II.1								

508 **Figures**



509 510 Figure 1. Clinical characteristics of the variants of POU1F1 beta coding region

- 511 A. Pedigrees and the sequence of the patients. Family 1-4 have variants in the POU1F1 beta
- 512 coding region: c.148T>G (p.S50A), c.152T>G (p.I51S), c.155T>G (p.L52W), and c.157T>G
- 513 (p.S53A). B. Growth curve of the patients from Family 2 and 4. GH replacement therapy was
- 514 effective in reaching ideal height.



515

516 Figure 2. Variants in the *POU1F1* beta coding region suppress the function of alpha 517 isoform and lead to splicing abnormality.

A. Schematic of the human POU1F1 gene and protein isoforms produced by use of alternate 518 519 splice acceptors at exon 2. The Poulf1 beta isoform has an insertion of 26 amino acids located 520 at amino acid 48 in the transactivation domain. **B.** COS-7 cells were transfected with a *Pou1f1*luciferase reporter gene and expression vectors for POU1F1 alpha or beta isoforms either singly 521 522 or together in the ratios indicated (2N and 1N). WT POU1F1 alpha has strong activation at 2N and 1N dosages. WT and variants of POU1F1 beta isoform have no significant activation over 523 524 background. A 50:50 mix of alpha and WT beta isoforms exhibited reduced activation. The 525 variant beta isoforms suppress alpha isoform mediated activation to a degree similar to WT. C. Diagram of the splice acceptor site consensus and the genomic DNA sequence at the boundary 526 between intron 1 and splice sites utilized in exon 2 of the *POU1F1* gene⁷¹ **D.** Evolutionary 527 528 conservation of the genomic sequence encoding POU1F1 beta isoform in mammals and 529 chicken. E. Exon trapping assay with pSPL3 exon trap vector containing exon 2 of POU1F1 530 and portions of the flanking introns. F. Ethidium bromide-stained gel of exon trap products from 531 cells transfected with the indicated plasmid. Arrowheads indicate the expected products for 532 exon skipping (Blue), alpha isoform (Yellow), and beta isoform (green). G. POU1F1 minigenes 533 spanning from intron 1 to 5, with all of the intervening exons, were engineered with the indicated 534 variants and assayed for splicing. WT and p.76L POU1F1 splice to produce the alpha isoform, 535 the G>T change in the splice acceptor causes exon skipping (red arrow) and the other patient 536 variants all splice to produce POU1F1 beta isoform.



537



539 **IGHD** families with synonymous changes.

540 A. Percent usage of *POU1F1* exon 2 beta (top panel), skip (middle), and other isoforms

541 (bottom) by variant position as measured by massively parallel minigene assay. Gray bars

542 denote splicing-neutral variants, while colored bars indicate the base pair change of each SDV.

543 Cropped intronic regions are shown in **Suppl. Fig. 4**.

B. A cluster of SDVs near the beta isoform splice acceptor leads to increased usage of the beta isoform, and in some cases, increased exon skipping. Diamonds colored by the alternate allele indicate patient variants, and empty diamonds indicate variants reported in gnomAD. Missense variants' labels are in bold text.

548 **C**. Families 5 and 6 each had two individuals affected with IGHD and synonymous variants that

549 were splice disruptive. Pedigrees and Sanger sequence confirmation of variants are shown.

551 Acknowledgements

- 552 This work was supported by the National Institutes of Health (R01HD097096 to SAC), the Japan
- 553 Society for Promotion of Science (HB), Grant 2013/03236-5 from the São Paulo Research
- 554 Foundation (FAPESP) (IJPA), a grant from Pfizer (RP), and the Argentinean National Agency of
- 555 Scientific and Technical Promotion, PICT 2016-2913 and PICT 2017-0002 (MIPM).
- 556

557 Author Contributions

- 558 <u>Transfection and exon trapping</u>: Peter Gergics
- 559 Families 1, 3 and 6 patient collection and candidate gene screening: Frederic Castinetti,
- 560 Frédérique Albarel, Alexandru Saveanu, Anne Barlier, Thierry Brue
- 561 Family 2 patient collection and candidate gene screening: Alexander Jorge, Luciani Renata
- 562 Silveira Carvalho, Marilena Nakaguma, Berenice B Mendonça, Ivo JP Arnhold
- 563 Family 4 patient collection and WES: Denise Rockstroh-Lippold, Julia Hoppmann, Rami Abou
- 564 Jamra, Roland Pfaeffle
- 565 Family 5 patient collection: Debora Braslavsky, Ana Keselman, Ignacio Bergadá
- 566 Family 1 WES and analysis: Qing Fang, A Bilge Ozel, Qianyi Ma, Jun Z. Li
- 567 Family 2 WES and analysis: Michael H. Guo, Andrew Dauber
- 568 Family 5 WES and analysis: Sebastian Vishnopolska, Julian Martinez Mayer, Marcelo Martí,
- 569 María Ines Pérez Millán
- 570 High throughput mutagenesis and analysis: Cathy Smith, Mariam Maksutova, Jacob O. Kitzman
- 571 Wrote manuscript: Hironori Bando, Cathy Smith, Jacob O. Kitzman, Sally A. Camper
- 572

573 **Competing Interests statement**

574 The authors declare no competing interest in connection with this manuscript.

575 Materials & Correspondence

- 576 Sally A. Camper
- 577 Telephone: 734-763-0682
- 578 Email: <u>scamper@med.umich.edu</u>
- 579
- 580 Jacob O. Kitzman
- 581 Telephone: 734-764-9587
- 582 email: kitzmanj@umich.edu
- 583
- 584 Mailing address:
- 585 Camper or Kitzman
- 586 Dept. Human Genetics
- 587 University of Michigan Medical School
- 588 4909 Buhl Building
- 589 1241 Catherine St.
- 590 Ann Arbor, MI. 48198-5618
- 591
- 592 Fax: 734-763-3784
- 593
- 594
- 595

596 References

597 Ingraham, H. A. et al. The POU-specific domain of Pit-1 is essential for sequence-specific, 1 598 high affinity DNA binding and DNA-dependent Pit-1-Pit-1 interactions. Cell 61, 1021-599 1033. doi:10.1016/0092-8674(90)90067-o (1990). 600 Gordon, D. F. et al. Analysis of Pit-1 in regulating mouse TSH beta promoter activity in 2 601 thyrotropes. Mol Cell Endocrinol 96, 75-84, doi:10.1016/0303-7207(93)90097-4 (1993). 602 Davis, S. W., Keisler, J. L., Perez-Millan, M. I., Schade, V. & Camper, S. A. All Hormone-3 603 Producing Cell Types of the Pituitary Intermediate and Anterior Lobes Derive From 604 Prop1-Expressing Progenitors. Endocrinology 157, 1385-1396, doi:10.1210/en.2015-605 1862 (2016). 606 Li, S. et al. Dwarf locus mutants lacking three pituitary cell types result from mutations in the 4 607 POU-domain gene pit-1. Nature 347, 528-533, doi:10.1038/347528a0 (1990). 608 Camper, S. A., Saunders, T. L., Katz, R. W. & Reeves, R. H. The Pit-1 transcription factor 5 609 gene is a candidate for the murine Snell dwarf mutation. *Genomics* **8**, 586-590 (1990). 610 Simmons, D. M. et al. Pituitary cell phenotypes involve cell-specific Pit-1 mRNA translation 6 611 and synergistic interactions with other classes of transcription factors. Genes Dev 4, 612 695-711, doi:10.1101/gad.4.5.695 (1990). Slabaugh, M. B., Lieberman, M. E., Rutledge, J. J. & Gorski, J. Growth hormone and 613 7 614 prolactin synthesis in normal and homozygous Snell and Ames dwarf mice. 615 Endocrinology 109, 1040-1046, doi:10.1210/endo-109-4-1040 (1981). Lin, S. C., Li, S., Drolet, D. W. & Rosenfeld, M. G. Pituitary ontogeny of the Snell dwarf 616 8 617 mouse reveals Pit-1-independent and Pit-1-dependent origins of the thyrotrope. 618 Development 120, 515-522 (1994). 619 9 Pfaffle, R. & Klammt, J. Pituitary transcription factors in the aetiology of combined pituitary 620 hormone deficiency. Best Pract Res Clin Endocrinol Metab 25, 43-60, 621 doi:10.1016/j.beem.2010.10.014 (2011). 622 10 Wallis, M. Evolution of the POU1F1 transcription factor in mammals: Rapid change of the 623 alternatively-spliced beta-domain. Gen Comp Endocrinol 260, 100-106, 624 doi:10.1016/j.ygcen.2018.01.005 (2018). 625 11 Schanke, J. T., Conwell, C. M., Durning, M., Fisher, J. M. & Golos, T. G. Pit-1/growth 626 hormone factor 1 splice variant expression in the rhesus monkey pituitary gland and the 627 rhesus and human placenta. J Clin Endocrinol Metab 82, 800-807, 628 doi:10.1210/jcem.82.3.3791 (1997). 629 12 Konzak, K. E. & Moore, D. D. Functional isoforms of Pit-1 generated by alternative 630 messenger RNA splicing. Mol Endocrinol 6, 241-247, doi:10.1210/mend.6.2.1569967 631 (1992). 632 13 Haugen, B. R., Wood, W. M., Gordon, D. F. & Ridgway, E. C. A thyrotrope-specific variant of 633 Pit-1 transactivates the thyrotropin beta promoter. J Biol Chem 268, 20818-20824 634 (1993). 14 Jonsen, M. D., Duval, D. L. & Gutierrez-Hartmann, A. The 26-amino acid beta-motif of the 635 636 Pit-1beta transcription factor is a dominant and independent repressor domain. Mol 637 Endocrinol 23, 1371-1384, doi:10.1210/me.2008-0137 (2009). 638 15 Consortium, G. T. The GTEx Consortium atlas of genetic regulatory effects across human 639 tissues. Science 369, 1318-1330, doi:10.1126/science.aaz1776 (2020). 640 16 Tatsumi, K. et al. Cretinism with combined hormone deficiency caused by a mutation in the 641 PIT1 gene. Nat Genet 1, 56-58, doi:10.1038/ng0492-56 (1992). 642 17 Fang, Q. et al. Genetics of Combined Pituitary Hormone Deficiency: Roadmap into the 643 Genome Era. Endocr Rev 37, 636-675, doi:10.1210/er.2016-1101 (2016). 644 18 Gergics, P. Pituitary Transcription Factor Mutations Leading to Hypopituitarism. Exp Suppl 645 111, 263-298, doi:10.1007/978-3-030-25905-1 13 (2019).

- Birla, S. *et al.* Characterization of a Novel POU1F1 Mutation Identified on Screening 160
 Growth Hormone Deficiency Patients. *Horm Metab Res* 51, 248-255, doi:10.1055/a 0867-1026 (2019).
- 649 20 Bas, F. *et al.* Precocious or early puberty in patients with combined pituitary hormone
 650 deficiency due to POU1F1 gene mutation: case report and review of possible
 651 mechanisms. *Hormones (Athens)* 17, 581-588, doi:10.1007/s42000-018-0079-4 (2018).
- Blum, W. F. *et al.* Screening a large pediatric cohort with GH deficiency for mutations in
 genes regulating pituitary development and GH secretion: Frequencies, phenotypes and
 growth outcomes. *EBioMedicine* **36**, 390-400, doi:10.1016/j.ebiom.2018.09.026 (2018).
- 655 22 Bertko, E. *et al.* Combined pituitary hormone deficiency due to gross deletions in the
 656 POU1F1 (PIT-1) and PROP1 genes. *J Hum Genet* 62, 755-762, doi:10.1038/jhg.2017.34
 657 (2017).
- Birla, S. *et al.* Identification of Novel PROP1 and POU1F1 Mutations in Patients with
 Combined Pituitary Hormone Deficiency. *Horm Metab Res* 48, 822-827, doi:10.1055/s 0042-117112 (2016).
- 661 24 Sobrier, M. L. *et al.* Functional characterization of a human POU1F1 mutation associated
 662 with isolated growth hormone deficiency: a novel etiology for IGHD. *Hum Mol Genet* 25,
 663 472-483, doi:10.1093/hmg/ddv486 (2016).
- Cohen, L. E., Zanger, K., Brue, T., Wondisford, F. E. & Radovick, S. Defective retinoic acid
 regulation of the Pit-1 gene enhancer: a novel mechanism of combined pituitary
 hormone deficiency. *Mol Endocrinol* **13**, 476-484, doi:10.1210/mend.13.3.0251 (1999).
- 667 26 Skowronska-Krawczyk, D. *et al.* Required enhancer-matrin-3 network interactions for a
 668 homeodomain transcription program. *Nature* **514**, 257-261, doi:10.1038/nature13573
 669 (2014).
- 670 27 Guo, M. H. *et al.* Whole exome sequencing to identify genetic causes of short stature. *Horm* 671 *Res Paediatr* **82**, 44-52, doi:10.1159/000360857 (2014).
- 872 28 Nisson, P. E., Ally, A. & Watkins, P. C. Protocols for trapping internal and 3'-terminal exons.
 873 *PCR Methods Appl* 4, S24-39, doi:10.1101/gr.4.1.s24 (1994).
- 4 29 Hiatt, J. B., Patwardhan, R. P., Turner, E. H., Lee, C. & Shendure, J. Parallel, tag-directed
 assembly of locally derived short sequence reads. *Nat Methods* 7, 119-122,
 doi:10.1038/nmeth.1416 (2010).
- 30 Zorita, E., Cusco, P. & Filion, G. J. Starcode: sequence clustering based on all-pairs search.
 Bioinformatics 31, 1913-1919, doi:10.1093/bioinformatics/btv053 (2015).
- 679 31 Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing.
 680 arXiv.org 1207.3907v2 (2012).
- 32 Wu, T. D. & Watanabe, C. K. GMAP: a genomic mapping and alignment program for mRNA
 and EST sequences. *Bioinformatics* 21, 1859-1875, doi:10.1093/bioinformatics/bti310
 (2005).
- 33 Rosenberg, A. B., Patwardhan, R. P., Shendure, J. & Seelig, G. Learning the sequence
 determinants of alternative splicing from millions of random sequences. *Cell* 163, 698 711, doi:10.1016/j.cell.2015.09.054 (2015).
- 34 Xiong, H. Y. *et al.* RNA splicing. The human splicing code reveals new insights into the
 genetic determinants of disease. *Science* 347, 1254806, doi:10.1126/science.1254806
 (2015).
- 35 Jaganathan, K. *et al.* Predicting Splicing from Primary Sequence with Deep Learning. *Cell* **176**, 535-548 e524, doi:10.1016/j.cell.2018.12.015 (2019).
- 692 36 Cheng, J. *et al.* MMSplice: modular modeling improves the predictions of genetic variant
 693 effects on splicing. *Genome Biol* 20, 48, doi:10.1186/s13059-019-1653-z (2019).
- 69437 Ke, S. et al. Quantitative evaluation of all hexamers as exonic splicing elements. Genome695Res 21, 1360-1374, doi:10.1101/gr.119628.110 (2011).

- 696 38 Ray, D. *et al.* A compendium of RNA-binding motifs for decoding gene regulation. *Nature*697 **499**, 172-177, doi:10.1038/nature12311 (2013).
- 698 39 Lerario, A. M. *et al.* SELAdb: A database of exonic variants in a Brazilian population referred
 699 to a quaternary medical center in Sao Paulo. *Clinics (Sao Paulo)* **75**, e1913,
 700 doi:10.6061/clinics/2020/e1913 (2020).
- 40 Vishnopolska, S. A. *et al.* Genetics and genomic medicine in Argentina. *Mol Genet Genomic Med*, doi:10.1002/mgg3.455 (2018).
- 41 Ho, Y., Cooke, N. E. & Liebhaber, S. A. An autoregulatory pathway establishes the definitive
 chromatin conformation at the pit-1 locus. *Mol Cell Biol* 35, 1523-1532,
 doi:10.1128/MCB.01283-14 (2015).
- 42 Yeo, G. & Burge, C. B. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J Comput Biol* **11**, 377-394, doi:10.1089/1066527041410418 (2004).
- 70943 Inoue, H. et al. Identification of a novel mutation in the exon 2 splice donor site of the710POU1F1/PIT-1 gene in Japanese identical twins with mild combined pituitary hormone711deficiency. Clin Endocrinol (Oxf) 76, 78-87, doi:10.1111/j.1365-2265.2011.04165.x712(2012).
- 44 Takagi, M. *et al.* A novel heterozygous intronic mutation in POU1F1 is associated with
 combined pituitary hormone deficiency. *Endocr J* 64, 229-234,
 doi:10.1507/endocrj.EJ16-0361 (2017).
- 45 Cerbone, M. & Dattani, M. T. Progression from isolated growth hormone deficiency to
 combined pituitary hormone deficiency. *Growth Horm IGF Res* 37, 19-25,
 doi:10.1016/j.ghir.2017.10.005 (2017).
- 46 Turton, J. P. *et al.* Novel mutations within the POU1F1 gene associated with variable
 combined pituitary hormone deficiency. *J Clin Endocrinol Metab* **90**, 4762-4770,
 doi:10.1210/jc.2005-0570 (2005).
- 47 Solomon, B. D. *et al.* Analysis of genotype-phenotype correlations in human
 holoprosencephaly. *Am J Med Genet C Semin Med Genet* 154C, 133-141,
 doi:10.1002/ajmg.c.30240 (2010).
- 48 Domene, S. *et al.* Mutations in the human SIX3 gene in holoprosencephaly are loss of
 function. *Hum Mol Genet* 17, 3919-3928, doi:10.1093/hmg/ddn294 (2008).
- 49 Gaston-Massuet, C. *et al.* Genetic interaction between the homeobox transcription factors
 HESX1 and SIX3 is required for normal pituitary development. *Dev Biol* 324, 322-333,
 doi:10.1016/j.ydbio.2008.08.008 (2008).
- For Holloway, J. M., Szeto, D. P., Scully, K. M., Glass, C. K. & Rosenfeld, M. G. Pit-1 binding to
 specific DNA sites as a monomer or dimer determines gene-specific use of a tyrosinedependent synergy domain. *Genes Dev* 9, 1992-2006, doi:10.1101/gad.9.16.1992
 (1995).
- 734 51 Rhodes, S. J. *et al.* A tissue-specific enhancer confers Pit-1-dependent morphogen
 735 inducibility and autoregulation on the pit-1 gene. *Genes Dev* 7, 913-932 (1993).
- 52 Cohen, R. N. *et al.* The role of CBP/p300 interactions and Pit-1 dimerization in the
 pathophysiological mechanism of combined pituitary hormone deficiency. *J Clin Endocrinol Metab* **91**, 239-247, doi:10.1210/jc.2005-1211 (2006).
- Theill, L. E., Hattori, K., Lazzaro, D., Castrillo, J. L. & Karin, M. Differential splicing of the
 GHF1 primary transcript gives rise to two functionally distinct homeodomain proteins.
 EMBO J 11, 2261-2269 (1992).
- 54 Lim, L. P. & Burge, C. B. A computational analysis of sequence features involved in
 recognition of short introns. *Proc Natl Acad Sci U S A* 98, 11193-11198,
 doi:10.1073/pnas.201407298 (2001).

- 55 Cartegni, L., Chew, S. L. & Krainer, A. R. Listening to silence and understanding nonsense:
 exonic mutations that affect splicing. *Nat Rev Genet* 3, 285-298, doi:10.1038/nrg775
 (2002).
- 56 Cheung, R. *et al.* A Multiplexed Assay for Exon Recognition Reveals that an Unappreciated
 Fraction of Rare Genetic Variants Cause Large-Effect Splicing Disruptions. *Mol Cell* 73, 183-194 e188, doi:10.1016/j.molcel.2018.10.037 (2019).
- 57 König, J., Zarnack, K., Luscombe, N. M. & Ule, J. Protein-RNA interactions: new genomic technologies and perspectives. *Nat Rev Genet* 13, 77-83, doi:10.1038/nrg3141 (2012).
- 58 Salvatori, R. *et al.* Familial dwarfism due to a novel mutation of the growth hormonereleasing hormone receptor gene. *J Clin Endocrinol Metab* 84, 917-923,
 doi:10.1210/jcem.84.3.5599 (1999).
- Alatzoglou, K. S. & Dattani, M. T. Phenotype-genotype correlations in congenital isolated
 growth hormone deficiency (IGHD). *Indian J Pediatr* **79**, 99-106, doi:10.1007/s12098 011-0614-7 (2012).
- 60 Shariat, N., Holladay, C. D., Cleary, R. K., Phillips, J. A., 3rd & Patton, J. G. Isolated growth
 hormone deficiency type II caused by a point mutation that alters both splice site
 strength and splicing enhancer function. *Clin Genet* 74, 539-545, doi:10.1111/j.13990004.2008.01042.x (2008).
- 61 Berg, M. A., Guevara-Aguirre, J., Rosenbloom, A. L., Rosenfeld, R. G. & Francke, U.
 Mutation creating a new splice site in the growth hormone receptor genes of 37
 Ecuadorean patients with Laron syndrome. *Hum Mutat* 1, 24-32,
 doi:10.1002/humu.1380010105 (1992).
- Miletta, M. C., Lochmatter, D., Pektovic, V. & Mullis, P. E. Isolated growth hormone
 deficiency type 2: from gene to therapy. *Endocr Dev* 23, 109-120,
 doi:10.1159/000341766 (2012).
- Kuijper, E. C., Bergsma, A. J., Pijnappel, W. & Aartsma-Rus, A. Opportunities and challenges for antisense oligonucleotide therapies. *J Inherit Metab Dis*, doi:10.1002/jimd.12251 (2020).
- 64 Cummings, B. B. *et al.* Improving genetic diagnosis in Mendelian disease with transcriptome
 564 Sequencing. Sci Transl Med 9, doi:10.1126/scitranslmed.aal5209 (2017).
- 65 Scotti, M. M. & Swanson, M. S. RNA mis-splicing in disease. *Nat Rev Genet* 17, 19-32, doi:10.1038/nrg.2015.3 (2016).
- 66 Soemedi, R. *et al.* Pathogenic variants that alter protein code often disrupt splicing. *Nat Genet* 49, 848-855, doi:10.1038/ng.3837 (2017).
- 67 Lord, J. *et al.* Pathogenicity and selective constraint on variation near splice sites. *Genome* 780 *Res* 29, 159-170, doi:10.1101/gr.238444.118 (2019).
- 68 Khan, M. *et al.* Resolving the dark matter of ABCA4 for 1054 Stargardt disease probands
 through integrated genomics and transcriptomics. *Genet Med* 22, 1235-1246,
 doi:10.1038/s41436-020-0787-4 (2020).
- 69 Chen, J. M. *et al.* The Experimentally Obtained Functional Impact Assessments of 5' Splice
 Site GT'GC Variants Differ Markedly from Those Predicted. *Curr Genomics* 21, 56-66,
 doi:10.2174/1389202921666200210141701 (2020).
- 787 70 Dionnet, E. *et al.* Splicing impact of deep exonic missense variants in CAPN3 explored
 788 systematically by minigene functional assay. *Hum Mutat*, doi:10.1002/humu.24083
 789 (2020).
- 71 Ma, S. L. *et al.* Whole Exome Sequencing Reveals Novel PHEX Splice Site Mutations in
 Patients with Hypophosphatemic Rickets. *PLoS One* **10**, e0130729,
 doi:10.1371/journal.pone.0130729 (2015).
- 793

795 Supplementary Figures and Legends



Supplementary Figure 1. Clinical information for Family 4. Brain MRI of patient 1.1 (**A**, **B**; as a teenager) and 11.1 (**C-D**; as a pre-teen). Th

Brain MRI of patient I.1 (**A**, **B**; as a teenager) and II.1 (**C-D**; as a pre-teen). Thyroid ultrasound of patient I.2 (**E**) and II.1 (**F**). ¹Arteria carotis communis.



802 803

Supplementary Figure 2. Completeness and uniformity of saturation mutagenesis.

804 Stacked barplot showing, for each *POU1F1* variant by position (x-axis) and allele (color), the 805 number of distinct barcodes detected in RNA-seq data (median across replicates).



807

808 Supplementary Figure 3. Inter-replicate correlation.

A. Pairwise scatterplots of percent isoform use for beta, skip, other, and alpha isoforms among

810 the fourteen biological replicates. The median and range of Pearson's correlation values across

- 811 samples are shown for each isoform.
- 812 B. Histogram plotting the number of replicate samples in which variants met the splice disruptive
- variant (SDV) criteria; all SDVs met threshold in ≥ 8 replicates, with 96/113 found in all 14 replicates.
- 815



816 817

818 Supplementary Figure 4. Uncropped *POU1F1* splicing effect map

819 Uncropped version of **Figure 3A**, including cropped intronic regions lacking any SDVs. Isoform 820 usage and variants are plotted as in **Figure 3A**.

821





 $\overline{23}$ Supplementary Figure 5. Splice disruptive variants by isoform and variant type.

Distributions of isoform usage *z*-scores for each subset of subsets are shown as violin plots. Count within each intersection (and % of total) are shown above vertical bars. Count within each subset prior to intersection (and % of total) are shown along horizontal bars. UpSet plot showing splice disruptive variants (SDVs), categorized by isoform (beta, skip, and other) and variant type (exonic, intronic, and synonymous). Filled circles denote membership in multiple categories (e.g., second column from the left indicates there are 22 intronic SDVs causing increased skipping).



831 832

Supplementary Figure 6. Splice site strength for novel alternate donors and acceptors.

Splice site strength as predicted by MaxEntScan⁴² for novel alternate splice acceptor and donor sites. *P*-value corresponds to a *t*-test comparing the splice site strength for motifs at seldom used novel acceptor sites (n = 118) vs. motifs that promote use of another isoform at novel

acceptor sites (n = 27). Dashed line (purple) represents the splice site strength of the native

beta acceptor site. Solid lines (green) indicate the splice site strength of the native alpha

acceptor site and native donor site respectively. Splice site strength is truncated at -20 in the

positional plots, but minimum is as low as -31.6 for novel acceptors and donors within this exon.



⁸⁴¹ 842 843

844 Supplementary Figure 7. Alternate splice sites and frameshift mutations.

Detailed view of splicing effect measurements, plotted as in Figure 3B, focusing on native alpha
 acceptor site (left) and native donor site (right). Colored and unfilled diamonds indicate patient
 variants (colored by alternate allele) and gnomAD variants, respectively. Canonical and cryptic
 splice sites are boxed, red dashed lines demarcate canonical exon boundaries, and coding
 frame and corresponding amino acids are indicated below.



851 852

852 Supplementary Figure 8. Splice disruptive variants (SDVs) in gnomAD.

Violin plots of the log10 allele frequency for each variant found in gnomAD v2.1.1 (orange) and v3 (green) within each subset are shown. Count within each intersection (and % of total) are shown above vertical bars. Count within each subset prior to intersection (and % of total) are shown along horizontal bars. *P*-value corresponds to a Fisher's exact test comparing the proportion of splice disruptive variants between gnomAD variants and variants absent from gnomAD. UpSet plots showing intersection of tested variants with or without splice disruptive

- 859 effects, and gnomAD variants.
- 860
- 861
- 862



SPANR, and MMSplice (from second from the top to bottom y-axes).

864



869

870 Supplementary Figure 10. Evaluation of *in silico* splicing effect predictions.

871 A. Precision-recall curve showing the precision (y-axis) and recall (x-axis) of SpliceAI (blue)³⁵, ESRseq (orange)³⁷, HAL (green)³³, SPANR (purple)³⁴, and MMSplice (gray)³⁶ to predict splice disruptive variants (SDVs) in exonic regions. The 'x' is the at the minimum threshold where 872 873 874 SpliceAl predicts all of the patient variants as disruptive (SpliceAl deltaMax score ≥ 0.19). Area 875 under the curve (prAUC) is shown within the legend **B.** Same as in A but for intronic variants. 876 Since HAL and ESRseq values do not apply in noncoding regions so they are omitted from this 877 plot. C. Precision-recall curve of the precision (y-axis) and recall (x-axis) for SpliceAI prediction of measured splice disruption across varying zPSI thresholds (range: 1 - 3) to call variants as 878 879 disruptive. prAUC for each threshold is shown within the legend. D. Scatterplot of SpliceAI 880 prAUC (y-axis) at varying splice disruption z-thresholds (x-axis). 881



883 Supplementary Figure 11. RNA binding protein consensus binding motifs relative to 884 splice acceptor for *POU1F1* beta.

885 Barplots displaying match scores (y-axis) for selected motifs defined by RNACompete³⁸ scored

against the wild-type *POU1F1* sequence beta region (positions c.143-1 to to c.167).



888 Supplementary Figure 12. Changes in RNA binding protein motifs scores due to the

889 SNVs in *POU1F1* beta.

890 Barplots show the change in maximal RNAcompete kmer score (y-axis) by variant and 891 position (x-axis), relative to the same motif scored against the wild-type *POU1F1*

892 sequence. Black stars indicate SDVs that promote beta isoform splicing.

893

887

Supplemental Table 1. Summary functional effects of all variants tested near POU1F1 895 exon 2.